

*Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics*

## Cellanyx Diagnostics News – Announcement of New Board Member Dr. Samuel Sia

March 15, 2013

Cellanyx is pleased to announce the appointment of Dr. Samuel Sia to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Dr. Samuel Sia comes with tremendous business and leadership talent. Currently, Dr. Sia is an Associate Professor of Biomedical Engineering at Columbia University, specializing in microfluidics, point-of-care diagnostics, 3D tissue engineering, and implantable devices. He is the Co-Founder of Claros Diagnostics, where he helped the company develop a microfluidic chip to monitor prostate-cancer. He was listed in MIT's list of top 35 innovators under the age of 35 in 2010.

Dr. Sia is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

---

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.  
One Marina Park Drive,  
14th floor  
Boston, MA, 02210  
Main: 571.212.9991  
Email: [info@cellanyx.com](mailto:info@cellanyx.com)